ISC 2026 | Findings from the Phase III LAIS trial of the neuroprotectant loberamisal in acute ischemic stroke

The aim of the LAIS trial is to assess the efficacy and safety of the loberamisal, that is a novel neuroprotectant disturbing two pathways, which is the PSD95 and another is alpha-2-gaba receptor pathways. So this new neuroprotectant will be detected in the ischemic stroke within 48 hours of symptoms onset. And in all clinical trials, we have found that the loberamisal can improve 13% of the excellent functional outcome compared with the placebo for that kind of patients with the favorable safety profile. We have the primary efficacy outcome of the modified Rankin of 0 to 1 and the secondary primary outcome was modified Rankin 0 to 2 and the ordinal modified ranking scores and orders to secondary end points was consistent with the primary efficacy outcome but the change in this score of the baseline and the Barthel index was same with the placebo group. And for the safety outcome we have the SAE, AE, SUSAR and all core stats. All the safety outcomes were similar between the two groups. For the conclusion of the LAIS trial, maybe the LAIS trial gave us the confidence of the neuroprotectant to stroke patients. We have demonstrated that the loberamisal can improve the excellent functional outcomes of the stroke patients within 48 hours of symptoms onset. But the early needs change and the Barthel index was neutral. So maybe another clinical trial will be for maybe for the EVT or other control patients can have some other signals for these agents.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.